The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...
High-risk acute pulmonary embolism affects around 5% of all pulmonary embolisms and can take a dramatic course even in young ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...
News Medical on MSN3d
Research Reveals Top Treatment for High-Risk Pulmonary EmbolismA current study involving the University Hospital Bonn (UKB) has investigated which treatment strategy offers the best ...
New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.
Pulnovo Medical announced yesterday that it closed a Series C funding round worth proceeds of nearly $100 million.
The following is a summary of "Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study," ...
No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has ...
Inhibiting the AURKB enzyme significantly improves multiple measures of blood flow in rats with pulmonary arterial ...
International study with over 1,000 patients provides groundbreaking findings for clinical intensive care medicine - A current study involving the University Hospital Bonn (UKB) has investigated which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback